Hematological Indices and Sympathetic Block Response in Neuropathic Pain (HINSPAIN)
Hematological Inflammatory Indices as Predictors of Treatment Response to Sympathetic Nerve Blocks in Neuropathic Pain: A Prospective Observational Study
Studieoversigt
Status
Detaljeret beskrivelse
Neuropathic pain is a complex chronic pain condition involving inflammatory, neural, and immune-mediated mechanisms. Increasing evidence suggests that systemic inflammatory processes may contribute to the pathophysiology and persistence of neuropathic pain. Hematological inflammatory indices derived from routine complete blood count parameters have recently emerged as inexpensive and accessible biomarkers reflecting systemic inflammatory status.
Although several studies have investigated inflammatory markers in chronic pain syndromes, data regarding the relationship between hematological inflammatory indices and treatment response following sympathetic nerve block interventions in neuropathic pain are limited.
This prospective observational study aims to evaluate whether hematological inflammatory indices are associated with treatment outcomes in neuropathic pain patients treated with sympathetic nerve block procedures as part of routine clinical management. Adult patients diagnosed with neuropathic pain and scheduled for sympathetic nerve block treatment will be prospectively followed for 3 months.
Clinical outcomes including Numeric Rating Scale (NRS), DN4 and/or LANSS neuropathic pain scores, Global Perceived Effect (GPE), and analgesic consumption will be recorded. Hematological indices including NLR, PLR, MLR, SII, SIRI, AISI, and RDW will be calculated using routine hemogram parameters.
The study is designed as a non-interventional, single-center, prospective observational clinical study. The treatment approach will not be altered for research purposes.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Ülkü Sabuncu, Assoc prof
- Telefonnummer: 905337085212
- E-mail: sabuncuulku@gmail.com
Studiesteder
-
-
Cankaya
-
Ankara, Cankaya, Tyrkiet (Türkiye), 06680
- Rekruttering
- Ankara Bilkent City Hospital
-
Kontakt:
- Ülkü Sabuncu, Assoc prof
- Telefonnummer: 905337085212
- E-mail: sabuncuulku@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Diagnosis of neuropathic pain based on clinical evaluation
- DN4 and/or LANSS scores compatible with neuropathic pain
- Undergoing sympathetic nerve block as part of routine clinical treatment
- Availability of pre-treatment and follow-up hemogram parameters
- Ability to provide written informed consent
Exclusion Criteria:
- Age <18 years
- Active infection or acute inflammatory disease
- Active malignancy
- History of hematological disease
- Immunosuppressive therapy or systemic corticosteroid use
- Major surgery or severe trauma within the last month
- Pregnancy or breastfeeding
- Autoimmune or rheumatologic inflammatory disease
- Missing follow-up data
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Neuropathic Pain Cohort
Adult patients diagnosed with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care in the Algology Clinic of Ankara Bilkent City Hospital.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment Response at Month 3
Tidsramme: 3 th month
|
Treatment response will be defined as achieving at least 50% reduction in Numeric Rating Scale (NRS) pain score compared with baseline. NRS 0 means = no pain NRS 10 means= worst pain imaginable |
3 th month
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
NRS (Numeric Rating Scale Pain Score)
Tidsramme: Baseline and 3rd month
|
Change in pain intensity measured by the 0-10 Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.
|
Baseline and 3rd month
|
|
Change in Hematological Inflammatory Indices
Tidsramme: Baseline and 3rd monnth
|
Change in hematological inflammatory indices including NLR, PLR, MLR, SII, SIRI, AISI, and RDW from baseline to follow-up.
|
Baseline and 3rd monnth
|
|
GPE (Global Perceived Effect)
Tidsramme: 3rd month
|
Patient-reported global improvement after treatment assessed using the Global Perceived Effect scale.Patient-reported overall improvement after treatment assessed using a 7-point Global Perceived Effect scale. Scale Description:
Interpretation: Lower scores indicate better clinical improvement. Time Frame: Month 3 |
3rd month
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 13579
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .